{"id":"azathioprine","rwe":[],"_fda":{"id":"3582bd73-c190-955e-e063-6394a90a634f","set_id":"040d010a-b1b2-4db7-905d-8aa7f1bab0cd","openfda":{"nui":["N0000000233","M0015066","N0000175712","M0018169"],"unii":["MRK240IY2L"],"route":["ORAL"],"rxcui":["197388"],"spl_id":["3582bd73-c190-955e-e063-6394a90a634f"],"brand_name":["Azathioprine"],"spl_set_id":["040d010a-b1b2-4db7-905d-8aa7f1bab0cd"],"package_ndc":["68084-229-11","68084-229-01"],"product_ndc":["68084-229"],"generic_name":["AZATHIOPRINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Nucleosides [CS]","Purines [CS]"],"substance_name":["AZATHIOPRINE"],"pharm_class_epc":["Purine Antimetabolite [EPC]"],"pharm_class_moa":["Nucleic Acid Synthesis Inhibitors [MoA]"],"manufacturer_name":["American Health Packaging"],"application_number":["ANDA077621"],"original_packager_product_ndc":["68382-003"]},"version":"11","warnings":["WARNINGS Malignancy Patients receiving immunosuppressants, including azathioprine, are at increased risk of developing lymphoma and other malignancies, particularly of the skin. Physicians should inform patients of the risk of malignancy with azathioprine. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor. Post-transplant Renal transplant patients are known to have an increased risk of malignancy, predominantly skin cancer and reticulum cell or lymphomatous tumors. The risk of post-transplant lymphomas may be increased in patients who receive aggressive treatment with immunosuppressive drugs, including azathioprine. Therefore, immunosuppressive drug therapy should be maintained at the lowest effective levels. Rheumatoid Arthritis Information is available on the risk of malignancy with the use of azathioprine in rheumatoid arthritis (see ADVERSE REACTIONS ). It has not been possible to define the precise risk of malignancy due to azathioprine. The data suggest the risk may be elevated in patients with rheumatoid arthritis, though lower than for renal transplant patients. However, acute myelogenous leukemia as well as solid tumors have been reported in patients with rheumatoid arthritis who have received azathioprine. Inflammatory Bowel Disease Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with azathioprine. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Some of the patients were treated with azathioprine as monotherapy and some had received concomitant treatment with a TNFα blocker at or prior to diagnosis. The safety and efficacy of azathioprine for the treatment of Crohn's disease and ulcerative colitis have not been established. Cytopenias Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur in patients being treated with azathioprine. Severe bone marrow suppression may also occur. Hematologic toxicities are dose-related and may be more severe in renal transplant patients whose homograft is undergoing rejection. It is suggested that patients on azathioprine have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary. Delayed hematologic suppression may occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in or persistently low leukocyte count, or other evidence of bone marrow depression. Leukopenia does not correlate with therapeutic effect; therefore the dose should not be increased intentionally to lower the white blood cell count. TPMT or NUDT15 Deficiency Patients with thiopurine S-methyl transferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency may be at an increased risk of severe and life-threatening myelotoxicity if receiving conventional doses of azathioprine (see CLINICAL PHARMACOLOGY ). Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine. In patients with severe myelosuppression, consider evaluation for TPMT and NUDT15 deficiency (see PRECAUTIONS: Laboratory Tests ). Consider alternative therapy in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency (see DOSAGE AND ADMINISTRATION ). Serious infections Patients receiving immunosuppressants, including azathioprine, are at increased risk for bacterial, viral, fungal, protozoal, and opportunistic infections, including reactivation of latent infections. These infections may lead to serious, including fatal outcomes. Progressive Multifocal Leukoencephalopathy Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including azathioprine. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. Consider the diagnosis of PML in any patient presenting with new-onset neurological manifestations and consider consultation with a neurologist as clinically indicated. Consider reducing the amount of immunosuppression in patients who develop PML. In transplant patients, consider the risk that the reduced immunosuppression represents to the graft. Effect on Sperm in Animals Azathioprine has been reported to cause temporary depression in spermatogenesis and reduction in sperm viability and sperm count in mice at doses 10 times the human therapeutic dose; 1 a reduced percentage of fertile matings occurred when animals received 5 mg/kg. 2 Pregnancy Azathioprine tablets can cause fetal harm when administered to a pregnant woman. Azathioprine tablets should not be given during pregnancy without careful weighing of risk versus benefit. Whenever possible, use of azathioprine tablets in pregnant patients should be avoided. This drug should not be used for treating rheumatoid arthritis in pregnant women. 3 Azathioprine tablets are teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Abnormalities included skeletal malformations and visceral anomalies. 2 Postmarketing cases of intrahepatic cholestasis of pregnancy (ICP) have been reported in women treated with azathioprine during pregnancy. ICP symptoms and evaluated bile acid levels improved following azathioprine discontinuation. Discontinue azathioprine tablets if ICP develops in a pregnant woman. Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on azathioprine tablets. In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. At 10 weeks most features were normalized. DeWitte et al reported pancytopenia and severe immune deficiency in a preterm infant whose mother received 125 mg azathioprine and 12.5 mg prednisone daily. 5 There have been two published reports of abnormal physical findings. Williamson and Karp described an infant born with preaxial polydactyly whose mother received azathioprine 200 mg daily and prednisone 20 mg every other day during pregnancy. 6 Tallent et al described an infant with a large myelomeningocele in the upper lumbar region, bilateral dislocated hips, and bilateral talipes equinovarus. The father was on long-term azathioprine therapy. 7 Benefit versus risk must be weighed carefully before use of azathioprine tablets in patients of reproductive potential. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be advised to avoid becoming pregnant."],"pregnancy":["Pregnancy Azathioprine tablets can cause fetal harm when administered to a pregnant woman. Azathioprine tablets should not be given during pregnancy without careful weighing of risk versus benefit. Whenever possible, use of azathioprine tablets in pregnant patients should be avoided. This drug should not be used for treating rheumatoid arthritis in pregnant women. 3 Azathioprine tablets are teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Abnormalities included skeletal malformations and visceral anomalies. 2 Postmarketing cases of intrahepatic cholestasis of pregnancy (ICP) have been reported in women treated with azathioprine during pregnancy. ICP symptoms and evaluated bile acid levels improved following azathioprine discontinuation. Discontinue azathioprine tablets if ICP develops in a pregnant woman. Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on azathioprine tablets. In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. At 10 weeks most features were normalized. DeWitte et al reported pancytopenia and severe immune deficiency in a preterm infant whose mother received 125 mg azathioprine and 12.5 mg prednisone daily. 5 There have been two published reports of abnormal physical findings. Williamson and Karp described an infant born with preaxial polydactyly whose mother received azathioprine 200 mg daily and prednisone 20 mg every other day during pregnancy. 6 Tallent et al described an infant with a large myelomeningocele in the upper lumbar region, bilateral dislocated hips, and bilateral talipes equinovarus. The father was on long-term azathioprine therapy. 7 Benefit versus risk must be weighed carefully before use of azathioprine tablets in patients of reproductive potential. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be advised to avoid becoming pregnant."],"overdosage":["OVERDOSAGE The oral LD 50 s for single doses of azathioprine tablets in mice and rats are 2500 mg/kg and 400 mg/kg, respectively. Very large doses of this antimetabolite may lead to marrow hypoplasia, bleeding, infection, and death. About 30% of azathioprine is bound to serum proteins, but approximately 45% is removed during an 8-hour hemodialysis. 14 A single case has been reported of a renal transplant patient who ingested a single dose of 7500 mg azathioprine. The immediate toxic reactions were nausea, vomiting, and diarrhea, followed by mild leukopenia and mild abnormalities in liver function. The white blood cell count, SGOT, and bilirubin returned to normal 6 days after the overdose."],"references":["REFERENCES Clark JM. The mutagenicity of azathioprine in mice, Drosophila melanogaster, and Neurospora crassa. Mutat Res. 1975; 28:87-99. Data on file, Sebela Ireland Ltd. Tagatz GE, Simmons RL. Pregnancy after renal transplantation. Ann Intern Med. 1975; 82:113-114. Editorial Notes. Cote' CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974; 85:324-328. DeWitte DB, Buick MK, Cyran SE, et al. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr. 1984; 105:625-628. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1981; 58:247-250. Tallent MB, Simmons RL, Najarian JS. Birth defects in child of male recipient of kidney transplant. JAMA. 1970; 211: 1854-1855. Data on file, Sebela Ireland Ltd. Saarikoski S, Seppälä M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973; 115:1100-1106. Coulam CB, Moyer TP, Jiang NS, et al. Breast-feeding after renal transplantation. Transplant Proc. 1982; 14: 605-609. Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med. 1986; 104:651-655. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic veno-occlusive disease in renal transplant patients. Gastroenterology. 1986; 90:446-454. Weitz H, Gokel JM, Loeshke K, et al. Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch A Pathol Anat Histol. 1982; 395:245-256. Schusziarra V, Ziekursch V, Schlamp R, et al. Pharmacokinetics of azathioprine under haemodialysis. Int J Clin Pharmacol Biopharm. 1976; 14:298-302. Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety; Clinical Center Pharmacy Department and Cancer Nursing Services, National Institute of Health; 1992. US Dept of Health and Human Services. Public Health Service Publication NIH 92-2621. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985; 253:1590-1592. National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115. Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Aust. 1983; 1:426-428. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from The Mount Sinai Medical Center. CA Cancer J for Clinicians. 1983; 33:258-263. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033-1049. Yodaiken RE, Bennett D. OSHA Work-Practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm, 1996; 43:1193-1204."],"description":["DESCRIPTION Azathioprine is an immunosuppressive antimetabolite. Each uncoated azathioprine tablet intended for oral administration contains 25 mg or 50 mg or 75 mg or 100 mg of azathioprine. In addition, each tablet contains the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone and starch. Azathioprine is chemically 6-[(1-methyl-4-nitro-1 H -imidazol-5-yl)thio]-1 H -purine. The structural formula of azathioprine is: It is an imidazolyl derivative of 6-mercaptopurine and many of its biological effects are similar to those of the parent compound. Azathioprine, USP is a pale yellow, odorless powder. It is insoluble in water, soluble in dilute solutions of alkali hydroxides, sparingly soluble in dilute mineral acids, very slightly soluble in alcohol and in chloroform. The sodium salt of azathioprine is sufficiently soluble to make a 10 mg/mL water solution which is stable for 24 hours at 59° to 77°F (15° to 25°C). Azathioprine is stable in solution at neutral or acid pH but hydrolysis to mercaptopurine occurs in excess sodium hydroxide (0.1N), especially on warming. Conversion to mercaptopurine also occurs in the presence of sulfhydryl compounds such as cysteine, glutathione, and hydrogen sulfide. Structural Formula"],"precautions":["PRECAUTIONS General A gastrointestinal hypersensitivity reaction characterized by severe nausea and vomiting has been reported. These symptoms may also be accompanied by diarrhea, rash, fever, malaise, myalgias, elevations in liver enzymes, and occasionally, hypotension. Symptoms of gastrointestinal toxicity most often develop within the first several weeks of therapy with azathioprine tablets and are reversible upon discontinuation of the drug. The reaction can recur within hours after rechallenge with a single dose of azathioprine tablets. Information for Patients Patients being started on azathioprine tablets should be informed of the necessity of periodic blood counts while they are receiving the drug and should be encouraged to report any unusual bleeding or bruising to their physician. They should be informed of the danger of infection while receiving azathioprine tablets and asked to report signs and symptoms of infection to their physician. Careful dosage instructions should be given to the patient, especially when azathioprine tablets are being administered in the presence of impaired renal function or concomitantly with allopurinol (see Drug Interactions subsection and DOSAGE AND ADMINISTRATION ). Patients should be advised of the potential risks of the use of azathioprine tablets during pregnancy and during the nursing period. The increased risk of malignancy following therapy with azathioprine tablets should be explained to the patient. Laboratory Tests Complete Blood Count (CBC) Monitoring Patients on azathioprine tablets should have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary. TPMT and NUDT15 Testing Consider genotyping or phenotyping patients for TPMT deficiency and genotyping for NUDT15 deficiency in patients with severe myelosuppression. TPMT and NUDT15 testing cannot substitute for complete blood count (CBC) monitoring in patients receiving azathioprine. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION sections). Drug Interactions Use with xanthine oxidase (XO) inhibitors: One of the pathways for inactivation of azathioprine is inhibited by XO inhibitors (allopurinol or febuxostat). Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/ 3 to 1/ 4 the usual dose. Concomitant use of azathioprine with febuxostat is not recommended. Inhibition of XO may cause increased plasma concentrations of azathioprine or its metabolite, 6-MP, leading to toxicity. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine and xanthine oxidase inhibitors because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY , WARNINGS , PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections). Use with Aminosalicylates There is in vitro evidence that aminosalicylate derivatives (e.g., sulphasalazine, mesalazine, or olsalazine) inhibit the TPMT enzyme. Concomitant use of these agents with azathioprine tablets should be done with caution. Use with Other Agents Affecting Myelopoesis Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients. Use with Angiotensin-Converting Enzyme Inhibitors The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia. Use with Warfarin Azathioprine tablets may inhibit the anticoagulant effect of warfarin. Use with ribavirin The use of ribavirin for hepatitis C in patients receiving azathioprine has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity. Inosine monophosphate dehydrogenase (IMDH) is required for one of the metabolic pathways of azathioprine. Ribavirin is known to inhibit IMDH, thereby leading to accumulation of an azathioprine metabolite, 6-methylthioionosine monophosphate (6MTITP), which is associated with myelotoxicity (neutropenia, thrombocytopenia, and anemia). Patients receiving azathioprine with ribavirin should have complete blood counts, including platelet counts, monitored weekly for the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage or other therapy changes are necessary. Carcinogenesis, Mutagenesis, Impairment of Fertility See WARNINGS section . Pregnancy: Teratogenic Effects See WARNINGS section. Nursing Mothers The use of azathioprine tablets in nursing mothers is not recommended. Azathioprine or its metabolites are transferred at low levels, both transplacentally and in breast milk. 8, 9, 10 Because of the potential for tumorigenicity shown for azathioprine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and efficacy of azathioprine in pediatric patients have not been established."],"how_supplied":["HOW SUPPLIED Azathioprine Tablets USP, 50 mg are yellow, round, flat, beveled edge tablets with bisect on one side; one side of the bisect is debossed with logo of \"ZC\" and other side is debossed with \"59\" and other side is plain and are supplied as follows: Unit dose packages of 100 (10 x 10) NDC 68084-229-01 STORAGE Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature] in a dry place and protect from light. FOR YOUR PROTECTION: Do not use if blister is torn or broken. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088."],"boxed_warning":["WARNING - MALIGNANCY Chronic immunosuppression with azathioprine, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with azathioprine. See WARNINGS ."],"pediatric_use":["Pediatric Use Safety and efficacy of azathioprine in pediatric patients have not been established."],"effective_time":"20250519","nursing_mothers":["Nursing Mothers The use of azathioprine tablets in nursing mothers is not recommended. Azathioprine or its metabolites are transferred at low levels, both transplacentally and in breast milk. 8, 9, 10 Because of the potential for tumorigenicity shown for azathioprine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests Complete Blood Count (CBC) Monitoring Patients on azathioprine tablets should have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary."],"adverse_reactions":["ADVERSE REACTIONS The principal and potentially serious toxic effects of azathioprine tablets are hematologic and gastrointestinal. The risks of secondary infection and malignancy are also significant (see WARNINGS ). The frequency and severity of adverse reactions depend on the dose and duration of azathioprine tablets as well as on the patient’s underlying disease or concomitant therapies. The incidence of hematologic toxicities and neoplasia encountered in groups of renal homograft recipients is significantly higher than that in studies employing azathioprine tablets for rheumatoid arthritis. The relative incidences in clinical studies are summarized below: Toxicity Renal Homograft Rheumatoid Arthritis * Data on the rate and risk of neoplasia among persons with rheumatoid arthritis treated with azathioprine are limited. The incidence of lymphoproliferative disease in patients with RA appears to be significantly higher than that in the general population. In one completed study, the rate of lymphoproliferative disease in RA patients receiving higher than recommended doses of azathioprine (5 mg/kg per day) was 1.8 cases per 1000 patient-years of follow-up, compared with 0.8 cases per 1000 patient-years of follow-up in those not receiving azathioprine. However, the proportion of the increased risk attributable to the azathioprine dosage or to other therapies (i.e., alkylating agents) received by patients treated with azathioprine cannot be determined. Leukopenia (any degree) >50% 28% <2,500 cells/mm 3 16% 5.3% Infections 20% <1% Neoplasia * Lymphoma 0.5% Others 2.8% Hematologic Leukopenia and/or thrombocytopenia are dose-dependent and may occur late in the course of therapy with azathioprine tablets. Dose reduction or temporary withdrawal may result in reversal of these toxicities. Infection may occur as a secondary manifestation of bone marrow suppression or leukopenia, but the incidence of infection in renal homotransplantation is 30 to 60 times that in rheumatoid arthritis. Anemias, including macrocytic anemia and/or bleeding have been reported. Patients with low or absent TPMT or NUDT15 activity are at increased risk for severe, life-threatening myelosuppression from azathioprine (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias and PRECAUTIONS: Laboratory Tests , DOSAGE AND ADMINISTRATION ). Gastrointestinal Nausea and vomiting may occur within the first few months of therapy with azathioprine tablets, and occurred in approximately 12% of 676 rheumatoid arthritis patients. The frequency of gastric disturbance often can be reduced by administration of the drug in divided doses and/or after meals. However, in some patients, nausea and vomiting may be severe and may be accompanied by symptoms such as diarrhea, fever, malaise, and myalgias (see PRECAUTIONS ). Vomiting with abdominal pain may occur rarely with a hypersensitivity pancreatitis. Hepatotoxicity manifest by elevation of serum alkaline phosphatase, bilirubin, and/or serum transaminases is known to occur following azathioprine use, primarily in allograft recipients. Hepatotoxicity has been uncommon (less than 1%) in rheumatoid arthritis patients. Hepatotoxicity following transplantation most often occurs within 6 months of transplantation and is generally reversible after interruption of azathioprine tablets. A rare, but life-threatening hepatic veno-occlusive disease associated with chronic administration of azathioprine has been described in transplant patients and in one patient receiving azathioprine tablets for panuveitis. 11, 12, 13 Periodic measurement of serum transaminases, alkaline phosphatase, and bilirubin is indicated for early detection of hepatotoxicity. If hepatic veno-occlusive disease is clinically suspected, azathioprine tablets should be permanently withdrawn. Others Additional side effects of low frequency have been reported. These include skin rashes, alopecia, fever, arthralgias, diarrhea, steatorrhea, negative nitrogen balance, reversible interstitial pneumonitis, hepatosplenic T-cell lymphoma (see Warnings - Malignancy ), and Sweet’s Syndrome ( acute febrile neutrophilic dermatosis ). Postmarketing Experience The following adverse reactions have been identified during postapproval use of azathioprine tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure. intrahepatic cholestasis of pregnancy (see WARNINGS, Pregnancy )."],"contraindications":["CONTRAINDICATIONS Azathioprine tablets should not be given to patients who have shown hypersensitivity to the drug. Azathioprine tablets should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with azathioprine tablets."],"drug_interactions":["Drug Interactions Use with xanthine oxidase (XO) inhibitors: One of the pathways for inactivation of azathioprine is inhibited by XO inhibitors (allopurinol or febuxostat). Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/ 3 to 1/ 4 the usual dose. Concomitant use of azathioprine with febuxostat is not recommended. Inhibition of XO may cause increased plasma concentrations of azathioprine or its metabolite, 6-MP, leading to toxicity. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine and xanthine oxidase inhibitors because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY , WARNINGS , PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections). Use with Aminosalicylates There is in vitro evidence that aminosalicylate derivatives (e.g., sulphasalazine, mesalazine, or olsalazine) inhibit the TPMT enzyme. Concomitant use of these agents with azathioprine tablets should be done with caution. Use with Other Agents Affecting Myelopoesis Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients. Use with Angiotensin-Converting Enzyme Inhibitors The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia. Use with Warfarin Azathioprine tablets may inhibit the anticoagulant effect of warfarin. Use with ribavirin The use of ribavirin for hepatitis C in patients receiving azathioprine has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity. Inosine monophosphate dehydrogenase (IMDH) is required for one of the metabolic pathways of azathioprine. Ribavirin is known to inhibit IMDH, thereby leading to accumulation of an azathioprine metabolite, 6-methylthioionosine monophosphate (6MTITP), which is associated with myelotoxicity (neutropenia, thrombocytopenia, and anemia). Patients receiving azathioprine with ribavirin should have complete blood counts, including platelet counts, monitored weekly for the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage or other therapy changes are necessary. Carcinogenesis, Mutagenesis, Impairment of Fertility See WARNINGS section ."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Azathioprine is well absorbed following oral administration. Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours. This is not an estimate of the half-life of azathioprine itself, but is the decay rate for all 35 S-containing metabolites of the drug. Because of extensive metabolism, only a fraction of the radioactivity is present as azathioprine. Usual doses produce blood levels of azathioprine, and of mercaptopurine derived from it, which are low (<1 mcg/mL). Blood levels are of little predictive value for therapy since the magnitude and duration of clinical effects correlate with thiopurine nucleotide levels in tissues rather than with plasma drug levels. Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable see OVERDOSAGE . Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6-TGNs) as major metabolites. The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA. 6-MP undergoes two major inactivation routes. One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). Another inactivation pathway is oxidation, which is catalyzed by xanthine oxidase (XO) to form 6-thiouric acid. The nucleotide diphosphatase (NUDT15) enzyme is involved in conversion of the 6-TGNs to inactive 6-TG monophosphates. TPMT activity correlates inversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities. Genetic polymorphisms influence TPMT and NUDT15 activity. Several published studies indicate that patients with reduced TPMT or NUDT15 activity receiving usual doses of 6-MP or azathioprine, accumulate excessive cellular concentrations of active 6-TGNs, and are at higher risk for severe myelosuppression. Because of the risk of toxicity, patients with TPMT or NUDT15 deficiency require alternative therapy or dose modification (see DOSAGE and ADMINISTRATION ). Approximately 0.3% (1:300) of patients of European or African ancestry have two loss-of-function alleles of the TPMT gene and have little or no TPMT activity (homozygous deficient or poor metabolizers), and approximately 10% of patients have one loss-of-function TPMT allele leading to intermediate TPMT activity (heterozygous deficient or intermediate metabolizers). The TPMT*2, TPMT*3A, and TPMT*3C alleles account for about 95% of individuals with reduced levels of TPMT activity. NUDT15 deficiency is detected in <1% of patients of European or African ancestry. Among patients of East Asian ancestry (i.e., Chinese, Japanese, Vietnamese), 2% have two loss-of-function alleles of the NUDT15 gene, and approximately 21% have one loss-of-function allele. The p.R139C variant of NUDT15 (present on the *2 and *3 alleles) is the most commonly observed, but other less common loss-of-function NUDT15 alleles have been observed. Inhibition of xanthine oxidase (XO) may cause increased plasma concentrations of azathioprine or its metabolites leading to toxicity (see PRECAUTIONS: Drug Interactions ). Proportions of metabolites are different in individual patients, and this presumably accounts for variable magnitude and duration of drug effects. Renal clearance is probably not important in predicting biological effectiveness or toxicities, although dose reduction is practiced in patients with poor renal function. Homograft Survival The use of azathioprine for inhibition of renal homograft rejection is well established, the mechanism(s) for this action are somewhat obscure. The drug suppresses hypersensitivities of the cell-mediated type and causes variable alterations in antibody production. Suppression of T-cell effects, including ablation of T-cell suppression, is dependent on the temporal relationship to antigenic stimulus or engraftment. This agent has little effect on established graft rejections or secondary responses. Alterations in specific immune responses or immunologic functions in transplant recipients are difficult to relate specifically to immunosuppression by azathioprine. These patients have subnormal responses to vaccines, low numbers of T-cells, and abnormal phagocytosis by peripheral blood cells, but their mitogenic responses, serum immunoglobulins, and secondary antibody responses are usually normal. Immunoinflammatory Response Azathioprine suppresses disease manifestations as well as underlying pathology in animal models of autoimmune disease. For example, the severity of adjuvant arthritis is reduced by azathioprine. The mechanisms whereby azathioprine affects autoimmune diseases are not known. Azathioprine is immunosuppressive, delayed hypersensitivity and cellular cytotoxicity tests being suppressed to a greater degree than are antibody responses. In the rat model of adjuvant arthritis, azathioprine has been shown to inhibit the lymph node hyperplasia, which precedes the onset of the signs of the disease. Both the immunosuppressive and therapeutic effects in animal models are dose-related. Azathioprine is considered a slow-acting drug and effects may persist after the drug has been discontinued."],"indications_and_usage":["INDICATIONS AND USAGE Azathioprine tablets, USP are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation Azathioprine tablets, USP are indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables. The effect of azathioprine tablets on these variables has not been tested in controlled trials. Rheumatoid Arthritis Azathioprine tablets, USP are indicated for the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. Aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with azathioprine tablets. The combined use of azathioprine tablets with disease modifying anti-rheumatic drugs (DMARDs) has not been studied for either added benefit or unexpected adverse effects. The use of azathioprine tablets with these agents cannot be recommended."],"adverse_reactions_table":["
ToxicityRenal HomograftRheumatoid Arthritis
*Data on the rate and risk of neoplasia among persons with rheumatoid arthritis treated with azathioprine are limited. The incidence of lymphoproliferative disease in patients with RA appears to be significantly higher than that in the general population. In one completed study, the rate of lymphoproliferative disease in RA patients receiving higher than recommended doses of azathioprine (5 mg/kg per day) was 1.8 cases per 1000 patient-years of follow-up, compared with 0.8 cases per 1000 patient-years of follow-up in those not receiving azathioprine. However, the proportion of the increased risk attributable to the azathioprine dosage or to other therapies (i.e., alkylating agents) received by patients treated with azathioprine cannot be determined.
Leukopenia (any degree)>50%28%
<2,500 cells/mm 316%5.3%
Infections20%<1%
Neoplasia*
Lymphoma0.5%
Others2.8%
"],"information_for_patients":["Information for Patients Patients being started on azathioprine tablets should be informed of the necessity of periodic blood counts while they are receiving the drug and should be encouraged to report any unusual bleeding or bruising to their physician. They should be informed of the danger of infection while receiving azathioprine tablets and asked to report signs and symptoms of infection to their physician. Careful dosage instructions should be given to the patient, especially when azathioprine tablets are being administered in the presence of impaired renal function or concomitantly with allopurinol (see Drug Interactions subsection and DOSAGE AND ADMINISTRATION ). Patients should be advised of the potential risks of the use of azathioprine tablets during pregnancy and during the nursing period. The increased risk of malignancy following therapy with azathioprine tablets should be explained to the patient."],"spl_unclassified_section":["PACKAGING INFORMATION American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Zydus Pharmaceuticals (USA) Inc. as follows: (50 mg / 100 UD) NDC 68084-229-01 packaged from NDC 68382-003 Distributed by: American Health Packaging Columbus, OH 43217 8222901/0325"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Renal Homotransplantation The dose of azathioprine tablets required to prevent rejection and minimize toxicity will vary with individual patients; this necessitates careful management. The initial dose is usually 3 to 5 mg/kg daily, beginning at the time of transplant. Azathioprine tablets are usually given as a single daily dose on the day of, and in a minority of cases 1 to 3 days before, transplantation. Dose reduction to maintenance levels of 1 to 3 mg/kg daily is usually possible. The dose of azathioprine tablets should not be increased to toxic levels because of threatened rejection. Discontinuation may be necessary for severe hematologic or other toxicity, even if rejection of the homograft may be a consequence of drug withdrawal. Rheumatoid Arthritis Azathioprine tablets are usually given on a daily basis. The initial dose should be approximately 1.0 mg/kg (50 to 100 mg) given as a single dose or on a twice-daily schedule. The dose may be increased, beginning at 6 to 8 weeks and thereafter by steps at 4-week intervals, if there are no serious toxicities and if initial response is unsatisfactory. Dose increments should be 0.5 mg/kg daily, up to a maximum dose of 2.5 mg/kg per day. Therapeutic response occurs after several weeks of treatment, usually 6 to 8; an adequate trial should be a minimum of 12 weeks. Patients not improved after 12 weeks can be considered refractory. Azathioprine tablets may be continued long-term in patients with clinical response, but patients should be monitored carefully, and gradual dosage reduction should be attempted to reduce risk of toxicities. Maintenance therapy should be at the lowest effective dose, and the dose given can be lowered decrementally with changes of 0.5 mg/kg or approximately 25 mg daily every 4 weeks while other therapy is kept constant. The optimum duration of maintenance azathioprine tablets has not been determined. Azathioprine tablets can be discontinued abruptly, but delayed effects are possible. Patients with TPMT and/or NUDT15 Deficiency Consider testing for TPMT and NUDT15 deficiency in patients who experience severe bone marrow toxicities. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , and PRECAUTIONS: Laboratory Tests ). Homozygous deficiency in either TPMT or NUDT15 Because of the risk of increased toxicity, consider alternative therapies for patients who are known to have TPMT or NUDT15 deficiency (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , and PRECAUTIONS: Laboratory Tests ). Heterozygous deficiency in TPMT and/or NUDT15 Because of the risk of increased toxicity, dosage reduction is recommended in patients known to have heterozygous deficiency of TPMT or NUDT15. Patients who are heterozygous for both TPMT and NUDT15 deficiency may require more substantial dosage reductions (see CLINICAL PHARMACOLOGY , WARNINGS: Cytopenias , and PRECAUTIONS: Laboratory Tests ). Use in Renal Dysfunction Relatively oliguric patients, especially those with tubular necrosis in the immediate postcadaveric transplant period, may have delayed clearance of azathioprine tablets or its metabolites, may be particularly sensitive to this drug, and are usually given lower doses. Procedures for proper handling and disposal of this immunosuppressive antimetabolite drug should be considered. Several guidelines on this subject have been published. 15-21 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate."],"spl_product_data_elements":["Azathioprine Azathioprine CROSCARMELLOSE SODIUM LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE, UNSPECIFIED STARCH, CORN AZATHIOPRINE AZATHIOPRINE YELLOW ROUND ZC;59"],"package_label_principal_display_panel":["Package/Label Display Panel – Carton – 50mg NDC 68084- 229 -01 Azathioprine Tablets, USP 50 mg 100 Tablets (10 x 10) Rx Only Each Tablet Contains: Azathioprine, USP............................................................50 mg Usual Dosage: See full prescribing information. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature] in a dry place and protect from light. FOR YOUR PROTECTION: Do not use if blister is torn or broken. The drug product contained in this package is from NDC # 68382-003, Zydus Pharmaceuticals USA, Inc. Distributed by: American Health Packaging, Columbus, Ohio 43217 110727 0222901/0324 50 mg Azathioprine Tablets Carton","Package/Label Display Panel – Blister – 50 mg Azathioprine Tablet, USP 50 mg 50 mg Azathioprine Tablet Blister"]},"tags":[{"label":"Purine Antimetabolite","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"ATP-binding cassette sub-family G member 2","category":"target"},{"label":"ABCG2","category":"gene"},{"label":"ABCC4","category":"gene"},{"label":"ABCC5","category":"gene"},{"label":"L04AX01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Oral","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Autoimmune hepatitis","category":"indication"},{"label":"Behcet's disease","category":"indication"},{"label":"Bullous pemphigoid","category":"indication"},{"label":"Crohn's disease","category":"indication"},{"label":"Dermatomyositis","category":"indication"},{"label":"Myasthenia gravis","category":"indication"},{"label":"Legacy Pharma","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antimetabolites, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Immunosuppressive Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING - MALIGNANCY Chronic immunosuppression with azathioprine, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with azathioprine. See WARNINGS ."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"13526 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"13163 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"6871 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"6109 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"5484 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5385 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"5365 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"4594 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"4393 reports"},{"date":"","signal":"CROHN^S DISEASE","source":"FDA FAERS","actionTaken":"4296 reports"}],"drugInteractions":[{"url":"/drug/balsalazide","drug":"balsalazide","action":"Monitor closely","effect":"May interact with Balsalazide","source":"DrugCentral","drugSlug":"balsalazide"},{"url":"/drug/mercaptopurine","drug":"mercaptopurine","action":"Avoid combination","effect":"May interact with Mercaptopurine","source":"DrugCentral","drugSlug":"mercaptopurine"},{"url":"/drug/mesalazine","drug":"mesalazine","action":"Monitor closely","effect":"May interact with Mesalamine","source":"DrugCentral","drugSlug":"mesalazine"},{"url":"/drug/olsalazine","drug":"olsalazine","action":"Monitor closely","effect":"May interact with Olsalazine","source":"DrugCentral","drugSlug":"olsalazine"},{"url":"/drug/sulfasalazine","drug":"sulfasalazine","action":"Monitor closely","effect":"May interact with Sulfasalazine","source":"DrugCentral","drugSlug":"sulfasalazine"},{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Leukopenia (any degree)","drugRate":">50%","_validated":true,"placeboRate":""},{"effect":"<2,500 cells/mm 3","drugRate":"16%","_validated":true,"placeboRate":"5.3%"},{"effect":"Infections","drugRate":"20%","_validated":true,"placeboRate":"<1%"},{"effect":"Lymphoma","drugRate":"0.5%","_validated":true,"placeboRate":""},{"effect":"Others","drugRate":"2.8%","_validated":true,"placeboRate":""},{"effect":"Nausea and vomiting","drugRate":"12%","_validated":true,"placeboRate":""}],"contraindications":["Acute pancreatitis","Anemia","Bacterial infectious disease","Bone marrow depression","Hepatic vein thrombosis","Hepatosplenic T-cell lymphoma","Impaired renal function disorder","Liver function tests abnormal","Malignant lymphoma","Mycosis","Pregnancy, function","Protozoal Infection","Severe Leukopenia","Thiopurine S-Methyltransferase Deficiency","Thrombocytopenic disorder","Viral disease"],"specialPopulations":{"Pregnancy":"Teratogenic Effects: Pregnancy Category D. See WARNINGS section.","Paediatric use":"Safety and efficacy of azathioprine in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Legacy Pharma","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$4.7909/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,749","description":"AZATHIOPRINE 100 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AZATHIOPRINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:58:51.329284+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:58:58.644520+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:58:49.476209+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZATHIOPRINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:58:59.469605+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:58:47.495869+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:58:47.495912+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING - MALIGNANCY Chronic immunosuppression with azathioprine, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignanc","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:58:47.495929+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:59:00.998968+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:59:00.034551+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1542/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:59.931316+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS The principal and potentially serious toxic effects of azathioprine tablets are hematologic and gastrointestinal. The risks of secondary infection and malignancy are also significant (see WARNINGS ). The frequency and severity of adverse reactions depend on the dose and duration of azathioprine tablets as well as on the patient’s underlying disease or concomitant therapies. The incidence of hematologic toxicities and neoplasia encountered in groups of renal homograft recipients","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:59:12.279718+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA077621","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:58:47.495938+00:00"}},"allNames":"imuran","offLabel":[],"synonyms":["BW 57-322","azathioprine sulfate","azathioprine","azamune","azanin","azathioprin","azathropine","azothioprine","azathioprine sodium"],"timeline":[{"date":"1968-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PROMETHEUS LABS to Legacy Pharma"},{"date":"1968-03-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Prometheus Labs)"},{"date":"1999-12-13","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"},{"date":"2019-02-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Aspen Japan K.K.; Mitsubishi Tanabe Pharma Corporation)"}],"aiSummary":"Imuran (Azathioprine) is a small molecule purine antimetabolite that targets ATP-binding cassette sub-family G member 2. It was originally developed by Prometheus Labs and is now owned by Legacy Pharma. Imuran is FDA-approved for various autoimmune diseases, including Crohn's disease, rheumatoid arthritis, and pemphigus vulgaris. The drug is available as a generic medication, with multiple manufacturers, and is off-patent. Key safety considerations include the risk of bone marrow suppression and increased susceptibility to infections.","brandName":"Imuran","ecosystem":[{"indication":"Autoimmune hepatitis","otherDrugs":[],"globalPrevalence":1880000},{"indication":"Behcet's disease","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"infliximab","slug":"infliximab","company":"Centocor Inc"}],"globalPrevalence":null},{"indication":"Bullous pemphigoid","otherDrugs":[],"globalPrevalence":2000000},{"indication":"Crohn's disease","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"budesonide","slug":"budesonide","company":""}],"globalPrevalence":5000000},{"indication":"Dermatomyositis","otherDrugs":[{"name":"benzoic acid","slug":"benzoic-acid","company":""}],"globalPrevalence":602496},{"indication":"Myasthenia gravis","otherDrugs":[{"name":"ambenonium","slug":"ambenonium","company":"Sanofi Aventis Us"},{"name":"efgartigimod alfa","slug":"efgartigimod-alfa","company":"Argenx Bv"},{"name":"neostigmine","slug":"neostigmine","company":"Eclat Pharms Llc"},{"name":"pyridostigmine","slug":"pyridostigmine","company":"Valeant Pharms Llc"}],"globalPrevalence":621600},{"indication":"Pemphigus vulgaris","otherDrugs":[{"name":"rituximab","slug":"rituximab","company":"Genentech"}],"globalPrevalence":1440000},{"indication":"Polyarteritis nodosa","otherDrugs":[],"globalPrevalence":252800}],"mechanism":{"target":"ATP-binding cassette sub-family G member 2","novelty":"Follow-on","targets":[{"gene":"ABCG2","source":"DrugCentral","target":"ATP-binding cassette sub-family G member 2","protein":"ATP-binding cassette sub-family G member 2"},{"gene":"ABCC4","source":"DrugCentral","target":"Multidrug resistance-associated protein 4","protein":"Multidrug resistance-associated protein 4"},{"gene":"ABCC5","source":"DrugCentral","target":"Multidrug resistance-associated protein 5","protein":"Multidrug resistance-associated protein 5"},{"gene":"RAC1","source":"DrugCentral","target":"Ras-related C3 botulinum toxin substrate 1","protein":"Ras-related C3 botulinum toxin substrate 1"},{"gene":"TPMT","source":"DrugCentral","target":"Thiopurine S-methyltransferase","protein":"Thiopurine S-methyltransferase"}],"moaClass":"Nucleic Acid Synthesis Inhibitors","modality":"Small Molecule","drugClass":"Purine Antimetabolite [EPC]","explanation":"","oneSentence":"","technicalDetail":"Imuran acts as a purine antimetabolite by inhibiting the enzyme xanthine oxidase, which is involved in the synthesis of purine nucleotides. This leads to the accumulation of 6-thioguanine nucleotides, which are incorporated into DNA and RNA, causing cytotoxic effects on rapidly dividing cells, including lymphocytes."},"commercial":{"launchDate":"1968","_launchSource":"DrugCentral (FDA 1968-03-20, PROMETHEUS LABS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/269","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AZATHIOPRINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZATHIOPRINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:52:17.811273","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:59:15.093526+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"thalidomide","drugSlug":"thalidomide","fdaApproval":"1998-07-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methotrexate","drugSlug":"methotrexate","fdaApproval":"1953-12-07","patentExpiry":"Oct 4, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lenalidomide","drugSlug":"lenalidomide","fdaApproval":"2005-12-27","patentExpiry":"Mar 8, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pirfenidone","drugSlug":"pirfenidone","fdaApproval":"2014-10-15","patentExpiry":"Sep 22, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pomalidomide","drugSlug":"pomalidomide","fdaApproval":"2013-02-08","patentExpiry":"Nov 19, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dimethyl fumarate","drugSlug":"dimethyl-fumarate","fdaApproval":"2013-03-27","patentExpiry":"Nov 16, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diroximel fumarate","drugSlug":"diroximel-fumarate","fdaApproval":"2019-10-29","patentExpiry":"Sep 20, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"azathioprine","indications":{"approved":[{"name":"Autoimmune hepatitis","source":"DrugCentral","snomedId":408335007,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":1880000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (ORPHANET_24326217[PMID])"},{"name":"Behcet's disease","source":"DrugCentral","snomedId":310701003,"regulator":"FDA"},{"name":"Bullous pemphigoid","source":"DrugCentral","snomedId":77090002,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":2000000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Crohn's disease","source":"DrugCentral","snomedId":34000006,"regulator":"FDA","usPrevalence":780000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"},{"name":"Dermatomyositis","source":"DrugCentral","snomedId":396230008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":602496,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (36581896[PMID]_ORPHANET)"},{"name":"Myasthenia gravis","source":"DrugCentral","snomedId":91637004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":621600,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (20565885[PMID])"},{"name":"Pemphigus vulgaris","source":"DrugCentral","snomedId":49420001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1440000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency[INST])"},{"name":"Polyarteritis nodosa","source":"DrugCentral","snomedId":155441006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":252800,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (9805179[PMID]_14872461[PMID]_17553910[PMID]_ORPHANET)"},{"name":"Prevention of Kidney Transplant Rejection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific patient eligibility criteria mentioned, but variables such as donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables affect patient survival."},{"name":"Refractory autoimmune haemolytic anaemia","source":"DrugCentral","snomedId":413603009,"regulator":"FDA"},{"name":"Refractory idiopathic thrombocytopenic purpura","source":"DrugCentral","snomedId":13172003,"regulator":"FDA"},{"name":"Relapsing multiple sclerosis","source":"DrugCentral","snomedId":24700007,"regulator":"FDA"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Systemic lupus erythematosus","source":"DrugCentral","snomedId":55464009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":3496000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (36241363[PMID])"},{"name":"Ulcerative colitis","source":"DrugCentral","snomedId":64766004,"regulator":"FDA","usPrevalence":900000,"globalPrevalence":5000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Gastroenterology, 2023"}],"offLabel":[{"name":"Polymyositis","source":"DrugCentral","drugName":"AZATHIOPRINE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Prevention of Cardiac Transplant Rejection","source":"DrugCentral","drugName":"AZATHIOPRINE","evidenceCount":279,"evidenceLevel":"strong"},{"name":"Prevention of Liver Transplant Rejection","source":"DrugCentral","drugName":"AZATHIOPRINE","evidenceCount":192,"evidenceLevel":"strong"},{"name":"Prevention of Lung Transplant Rejection","source":"DrugCentral","drugName":"AZATHIOPRINE","evidenceCount":137,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Legacy Pharma","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"thalidomide","brandName":"thalidomide","genericName":"thalidomide","approvalYear":"1998","relationship":"same-class"},{"drugId":"methotrexate","brandName":"methotrexate","genericName":"methotrexate","approvalYear":"1953","relationship":"same-class"},{"drugId":"lenalidomide","brandName":"lenalidomide","genericName":"lenalidomide","approvalYear":"2005","relationship":"same-class"},{"drugId":"pirfenidone","brandName":"pirfenidone","genericName":"pirfenidone","approvalYear":"2014","relationship":"same-class"},{"drugId":"pomalidomide","brandName":"pomalidomide","genericName":"pomalidomide","approvalYear":"2013","relationship":"same-class"},{"drugId":"dimethyl-fumarate","brandName":"dimethyl fumarate","genericName":"dimethyl fumarate","approvalYear":"2013","relationship":"same-class"},{"drugId":"diroximel-fumarate","brandName":"diroximel fumarate","genericName":"diroximel fumarate","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03323476","phase":"PHASE3","title":"Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2018-02-02","conditions":["Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","End Stage Renal Disease"],"enrollment":136,"completionDate":"2031-03"},{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":["Crohn Disease","Infliximab","Immunosuppression","Children, Only"],"enrollment":128,"completionDate":"2026-12-31"},{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":["Atopic Dermatitis"],"enrollment":1000,"completionDate":"2034-01-30"},{"nctId":"NCT07271069","phase":"","title":"Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-29","conditions":["Ulcerative Colitis (UC)"],"enrollment":150,"completionDate":"2027-12-31"},{"nctId":"NCT07424040","phase":"NA","title":"The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-01","conditions":["Crohn's Diseases","Crohn's Disease in Pediatric Patient"],"enrollment":154,"completionDate":"2028-11-30"},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":["Bronchiolitis Obliterans","Chronic Rejection of Lung Transplant","Lung Transplant Rejection","Lung Transplant; Complications","Lung Transplant Failure and Rejection","Chronic Lung Allograft Dysfunction"],"enrollment":169,"completionDate":"2024-03-12"},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":["Relapsing Polychondritis"],"enrollment":20,"completionDate":"2027-12"},{"nctId":"NCT05689879","phase":"PHASE3","title":"Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-23","conditions":["Sarcoidosis"],"enrollment":90,"completionDate":"2027-03"},{"nctId":"NCT04182984","phase":"","title":"TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2019-11-04","conditions":["Ocular Myasthenia Gravis"],"enrollment":200,"completionDate":"2026-06-30"},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":["Lupus or SLE","Interstitial Lung Disease","Systemic Lupus Erythematosus"],"enrollment":100,"completionDate":"2027-03-25"},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":["Colitis, Ulcerative"],"enrollment":672,"completionDate":"2026-03-31"},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":["Carcinoma, Hepatocellular"],"enrollment":336,"completionDate":"2027-03"},{"nctId":"NCT02939573","phase":"PHASE2","title":"A Randomized Multicenter Study for Isolated Skin Vasculitis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-01-01","conditions":["Primary Cutaneous Vasculitis","Cutaneous Polyarteritis Nodosa","IgA Vasculitis","Henoch-Schönlein Purpura"],"enrollment":90,"completionDate":"2028-12-31"},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Psoriasis","Atopic Dermatitis"],"enrollment":10,"completionDate":"2030-06-01"},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":["Eosinophilic Granulomatosis With Polyangiitis (EGPA)"],"enrollment":107,"completionDate":"2020-10-21"},{"nctId":"NCT06136767","phase":"","title":"Registry for Systemic Eczema Treatments","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-01-17","conditions":["Atopic Dermatitis"],"enrollment":400,"completionDate":"2030-12-31"},{"nctId":"NCT07235904","phase":"PHASE4","title":"Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis","status":"RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2025-12-05","conditions":["Ulcerative Colitis (UC)"],"enrollment":300,"completionDate":"2028-10"},{"nctId":"NCT05969730","phase":"NA","title":"Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2023-08-15","conditions":["Atopic Dermatitis"],"enrollment":40,"completionDate":"2025-11-14"},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":["Idiopathic Membranous Nephropathy"],"enrollment":200,"completionDate":"2029-12"},{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":["Ulcerative Colitis"],"enrollment":355,"completionDate":"2021-04-16"},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":["ANCA Associated Vasculitis (AAV)"],"enrollment":300,"completionDate":"2028-02-29"},{"nctId":"NCT00748644","phase":"PHASE3","title":"Efficacy Study of Two Treatments in the Remission of Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":["Wegener Granulomatosis","Microscopic Polyangiitis"],"enrollment":117,"completionDate":"2013-06"},{"nctId":"NCT03164473","phase":"PHASE3","title":"Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-07","conditions":["Eosinophilic Granulomatosis With Polyangiitis"],"enrollment":98,"completionDate":"2024-09-23"},{"nctId":"NCT05030155","phase":"PHASE3","title":"Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-30","conditions":["Eosinophilic Granulomatosis With Polyangiitis"],"enrollment":100,"completionDate":"2025-11"},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":["Sepsis and Septic Shock","Acute Respiratory Failure","Kidney Transplant Recipients","Immunosuppressive Agents"],"enrollment":212,"completionDate":"2029-06-01"},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":["Kidney Transplantation","Kidney Transplant Rejection"],"enrollment":20,"completionDate":"2024-02-23"},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":["Bronchiolitis Obliterans","Chronic Rejection of Lung Transplant","Lung Transplant Rejection","Lung Transplant; Complications","Lung Transplant Failure and Rejection","Chronic Lung Allograft Dysfunction"],"enrollment":62,"completionDate":"2024-04-16"},{"nctId":"NCT05249452","phase":"","title":"Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2018-03-08","conditions":["Sickle Cell Disease"],"enrollment":20,"completionDate":"2024-12-01"},{"nctId":"NCT01284725","phase":"PHASE3","title":"Weaning of Immunosuppression in Nephritis of Lupus","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-02-16","conditions":["Nephritis of Lupus"],"enrollment":100,"completionDate":"2018-12-31"},{"nctId":"NCT00647166","phase":"PHASE3","title":"Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-05","conditions":["MPA","PAN or EGPA With FFS=0","At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids"],"enrollment":114,"completionDate":"2015-04"},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":["Crohn Disease"],"enrollment":100,"completionDate":"2028-07-24"},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":["Rheumatic Disease"],"enrollment":80,"completionDate":"2027-09"},{"nctId":"NCT06476366","phase":"EARLY_PHASE1","title":"Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Pak Emirates Military Hospital","startDate":"2024-07-14","conditions":["Chronic Actinic Dermatitis"],"enrollment":20,"completionDate":"2025-07-02"},{"nctId":"NCT05646992","phase":"PHASE2,PHASE3","title":"Uterus Transplantation to Treat Infertility","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-01","conditions":["Uterine Factor Infertility"],"enrollment":40,"completionDate":"2043-02-28"},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":["Sickle Cell Disease"],"enrollment":40,"completionDate":"2029-08-01"},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":["Dermatomyositis"],"enrollment":62,"completionDate":"2026-02-28"},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":["Sickle Cell Disease"],"enrollment":21,"completionDate":"2026-12"},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":["Rheumatoid Arthritis"],"enrollment":400,"completionDate":"2029-03"},{"nctId":"NCT06243068","phase":"NA","title":"Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial","status":"ENROLLING_BY_INVITATION","sponsor":"George Washington University","startDate":"2024-11-13","conditions":["Chronic Kidney Disease"],"enrollment":3000,"completionDate":"2028-06-01"},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":["Lymphocytic Myocarditis (Disorder)","Heart Failure","Dilated Cardiomyopathy","Cardiomyopathies","Sudden Cardiac Death"],"enrollment":50,"completionDate":"2025-07-10"},{"nctId":"NCT06903130","phase":"","title":"Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2025-09-01","conditions":["NMOSD"],"enrollment":40,"completionDate":"2028-06-01"},{"nctId":"NCT07044141","phase":"PHASE1","title":"Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2025-03-01","conditions":["Vitiligo"],"enrollment":20,"completionDate":"2025-09-30"},{"nctId":"NCT07032337","phase":"","title":"Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-01-01","conditions":["Neuromyelitis Optica Spectrum Disorder (NMOSD)"],"enrollment":2985,"completionDate":"2022-12-31"},{"nctId":"NCT07012239","phase":"","title":"The Frequency of Thiopurine Methyltransferase Polymorphism in Systemic Lupus Erythematosus SLE","status":"COMPLETED","sponsor":"Bangladesh Medical University","startDate":"2016-01-01","conditions":["Genetic Polymorphism"],"enrollment":348,"completionDate":"2018-01-01"},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":["Crohn Disease","Azathioprine","Methotrexate"],"enrollment":166,"completionDate":"2027-05"},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":["Uveitis"],"enrollment":227,"completionDate":"2024-09-09"},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":["Crohn Disease"],"enrollment":100,"completionDate":"2027-03-01"},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":["Connective Tissue Diseases","Thrombocytopenia"],"enrollment":296,"completionDate":"2025-12"},{"nctId":"NCT06763848","phase":"NA","title":"Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-04-25","conditions":["Neuromyelitis Optica Spectrum Disorders"],"enrollment":144,"completionDate":"2026-12-31"},{"nctId":"NCT06925698","phase":"PHASE3","title":"Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease","status":"NOT_YET_RECRUITING","sponsor":"Marmara University","startDate":"2025-04-30","conditions":["Behcet Disease","Behcet Disease and Vascular Involvement","Deep Venous Thromboses","Post Thrombotic Syndrome"],"enrollment":110,"completionDate":"2028-04-01"},{"nctId":"NCT05321758","phase":"NA","title":"Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2020-03-22","conditions":["Crohn Disease"],"enrollment":50,"completionDate":"2027-06-30"},{"nctId":"NCT05545384","phase":"PHASE3","title":"Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":["Acute Demyelinating Syndrome"],"enrollment":86,"completionDate":"2030-04"},{"nctId":"NCT05060991","phase":"PHASE4","title":"Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-24","conditions":["COVID-19","Immunosuppression","Vaccine Response Impaired"],"enrollment":50,"completionDate":"2025-12-24"},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":["ANCA-Associated Vasculitis"],"enrollment":331,"completionDate":"2019-11-01"},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":["Skin Cancer"],"enrollment":44,"completionDate":"2011-04-19"},{"nctId":"NCT06226662","phase":"PHASE2","title":"Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":["Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"],"enrollment":12,"completionDate":"2028-09"},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":["Lung Transplant; Complications"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT06213857","phase":"PHASE2","title":"Beneficial Effect of Silymarin in Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-02-01","conditions":["Ulcerative Colitis"],"enrollment":44,"completionDate":"2025-06"},{"nctId":"NCT06846255","phase":"PHASE4","title":"Comparing DCP and DAP for Pemphigus Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2021-06-15","conditions":["Pemphigus Vulgaris"],"enrollment":66,"completionDate":"2021-12-15"},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":["Inflammatory Bowel Diseases"],"enrollment":15,"completionDate":"2024-07-04"},{"nctId":"NCT05349006","phase":"PHASE3","title":"Azathioprine in MOGAD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-12-12","conditions":["Central Nervous System Inflammation","MOG-IgG Associated Disease"],"enrollment":126,"completionDate":"2029-12-12"},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":["Granulomatosis with Polyangiitis","Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis"],"enrollment":42,"completionDate":"2029-01"},{"nctId":"NCT02852694","phase":"PHASE4","title":"Reduce Risk for Crohn's Disease Patients","status":"COMPLETED","sponsor":"PIBD-Net","startDate":"2017-02-28","conditions":["Crohn's Disease"],"enrollment":192,"completionDate":"2021-06-14"},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":["Kidney Transplant; Complications"],"enrollment":51,"completionDate":"2023-11-10"},{"nctId":"NCT06786689","phase":"PHASE2","title":"To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2023-03-01","conditions":["Alopecia Areata","Alopecia Areata(AA)"],"enrollment":60,"completionDate":"2023-09-30"},{"nctId":"NCT04660539","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":["Neuromyelitis Optica Spectrum Disorder"],"enrollment":119,"completionDate":"2024-05-28"},{"nctId":"NCT04106830","phase":"","title":"Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2019-01-01","conditions":["NMO Spectrum Disorder","MRI","Multiple Sclerosis","MOGAD"],"enrollment":1000,"completionDate":"2028-12-31"},{"nctId":"NCT02954939","phase":"NA","title":"The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-03-01","conditions":["Lupus Nephritis"],"enrollment":50,"completionDate":"2028-12-31"},{"nctId":"NCT06155604","phase":"PHASE2","title":"SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2023-01-04","conditions":["Lupus Nephritis","Chronic Kidney Diseases"],"enrollment":150,"completionDate":"2026-12-31"},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":["Inflammatory Disease","Disease Crohn","Bowel Disease"],"enrollment":158,"completionDate":"2025-12"},{"nctId":"NCT05149768","phase":"PHASE2","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-02-14","conditions":["Diffuse Cutaneous Systemic Sclerosis"],"enrollment":11,"completionDate":"2026-07-01"},{"nctId":"NCT06650124","phase":"PHASE2,PHASE3","title":"Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-11-01","conditions":["Autoimmune Hepatitis"],"enrollment":108,"completionDate":"2025-12-31"},{"nctId":"NCT06663943","phase":"PHASE1,PHASE2","title":"A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.","status":"NOT_YET_RECRUITING","sponsor":"Chao Ji","startDate":"2025-10-01","conditions":["Pemphigus Disease","Pemphigus Vulgaris (PV)"],"enrollment":100,"completionDate":"2026-11-01"},{"nctId":"NCT06654817","phase":"","title":"Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris","status":"COMPLETED","sponsor":"Chao Ji","startDate":"2023-01-01","conditions":["Pemphigus","Pemphigus Vulgaris (PV)"],"enrollment":38,"completionDate":"2024-04-01"},{"nctId":"NCT06637683","phase":"NA","title":"Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Anabio R&D","startDate":"2019-11-15","conditions":["Inflammatory Bowel Diseases"],"enrollment":60,"completionDate":"2020-06-20"},{"nctId":"NCT06126835","phase":"","title":"A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-26","conditions":["Ulcerative Colitis"],"enrollment":2828,"completionDate":"2032-06-30"},{"nctId":"NCT05891379","phase":"","title":"Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-07-09","conditions":["Neuromyelitis Optica Spectrum Disorder"],"enrollment":50,"completionDate":"2025-07-31"},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":["Wegener's Granulomatosis","Vasculitis"],"enrollment":84,"completionDate":"2015-01"},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":["Kidney Transplant Failure and Rejection"],"enrollment":20,"completionDate":"2027-12-03"},{"nctId":"NCT02426502","phase":"NA","title":"Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2016-04","conditions":["End-Stage Renal Disease"],"enrollment":76,"completionDate":"2024-12"},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":["Cutaneous Lupus Erythematosus"],"enrollment":3,"completionDate":"2022-10-18"},{"nctId":"NCT04654988","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2022-12-01","conditions":["Myocarditis","Heart Failure","Endomyocardial Biopsy","Cardiomyopathies, Secondary","Immunosuppression"],"enrollment":100,"completionDate":"2028-03-30"},{"nctId":"NCT02498977","phase":"PHASE4","title":"Liver Immunosuppression Free Trial","status":"TERMINATED","sponsor":"King's College London","startDate":"2015-10","conditions":["Transplantation, Liver"],"enrollment":116,"completionDate":"2021-12-31"},{"nctId":"NCT02517684","phase":"PHASE4","title":"Top-down Infliximab Study in Kids With Crohn's Disease","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2015-04","conditions":["Crohn's Disease"],"enrollment":100,"completionDate":"2024-01"},{"nctId":"NCT05458531","phase":"","title":"Monitoring of Inflammatory Conditions","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2022-06-28","conditions":["Inflammatory Disease","Crohn Disease","Ulcerative Colitis","Rheumatoid Arthritis","System; Lupus Erythematosus","Psoriatic Arthritis","Reactive Arthritis","Inflammatory Arthritis","Psoriasis"],"enrollment":664,"completionDate":"2023-02-08"},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":["Systemic Lupus Erythematosus"],"enrollment":92,"completionDate":"2023-11-13"},{"nctId":"NCT03871361","phase":"PHASE2","title":"Abatacept in Patients With Birdshot HLA A29 Uveitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-01","conditions":["Eye Diseases","Uveitis"],"enrollment":15,"completionDate":"2023-12-01"},{"nctId":"NCT02332356","phase":"PHASE3","title":"Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease","status":"UNKNOWN","sponsor":"Tokyo Medical and Dental University","startDate":"2014-09","conditions":["Crohn Disease"],"enrollment":100,"completionDate":"2024-03"},{"nctId":"NCT05263505","phase":"PHASE2","title":"Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2022-02-21","conditions":["Mucous Membrane Pemphigoid","Cicatrizing Conjunctivitis"],"enrollment":2,"completionDate":"2023-09-11"},{"nctId":"NCT04160325","phase":"NA","title":"Effect of the Exclusive Enteral Nutrition Combined With Azathioprine for Remission of Crohn's Diseases After Surgery","status":"UNKNOWN","sponsor":"Zhu Weiming","startDate":"2018-01-01","conditions":["Crohn Disease"],"enrollment":54,"completionDate":"2023-10-31"},{"nctId":"NCT03198689","phase":"PHASE2","title":"Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-07","conditions":["Diffuse Cutaneous Systemic Sclerosis"],"enrollment":11,"completionDate":"2023-08-28"},{"nctId":"NCT00143910","phase":"","title":"Natural History Study of Azathioprine Adherence","status":"COMPLETED","sponsor":"Thomas E. Nivens, MD","startDate":"1993-04","conditions":["Kidney Transplant"],"enrollment":180,"completionDate":"1999-10"},{"nctId":"NCT03096275","phase":"PHASE3","title":"Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis","status":"COMPLETED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2017-03-16","conditions":["Takayasu Arteritis"],"enrollment":138,"completionDate":"2022-11-11"},{"nctId":"NCT03445624","phase":"","title":"Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-07-01","conditions":["Inflammatory Bowel Diseases"],"enrollment":60,"completionDate":"2021-10-01"},{"nctId":"NCT05965284","phase":"PHASE4","title":"Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2023-03-09","conditions":["ANCA-associated Vasculitis","Maintenance Therapy"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":["Non-infectious Uveitis"],"enrollment":2000,"completionDate":"2028-08"},{"nctId":"NCT04304950","phase":"PHASE4","title":"Chronotherapy in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2016-04-25","conditions":["Inflammatory Bowel Diseases"],"enrollment":28,"completionDate":"2023-04"},{"nctId":"NCT02900443","phase":"PHASE4","title":"Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-01","conditions":["Autoimmune Hepatitis"],"enrollment":70,"completionDate":"2023-06"},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":["Inflammatory Bowel Diseases"],"enrollment":400,"completionDate":"2024-01"},{"nctId":"NCT05896605","phase":"PHASE4","title":"Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2020-01-01","conditions":["NMO Spectrum Disorder","Azathioprine Adverse Reaction"],"enrollment":63,"completionDate":"2023-04-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Azathioprine Sodium"},{"form":"TABLET","route":"ORAL","productName":"AZATHIOPRINE"},{"form":"TABLET","route":"ORAL","productName":"Azasan"},{"form":"TABLET","route":"ORAL","productName":"Azathioprine"},{"form":"TABLET","route":"ORAL","productName":"IMURAN"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147069","MMSL":"3341","NDDF":"003419","UNII":"MRK240IY2L","VUID":"4018766","VANDF":"4018766","INN_ID":"1291","RXNORM":"1256","UMLSCUI":"C0004482","chemblId":"CHEMBL1542","ChEMBL_ID":"CHEMBL1542","KEGG_DRUG":"D00238","DRUGBANK_ID":"DB00993","PUBCHEM_CID":"2265","SNOMEDCT_US":"111165009","IUPHAR_LIGAND_ID":"7120","SECONDARY_CAS_RN":"55774-33-9","MESH_DESCRIPTOR_UI":"D001379"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Prometheus Laboratories Inc.","brandName":"IMURAN","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1968-","companyName":"Prometheus Labs","relationship":"Original Developer"},{"period":"present","companyName":"Legacy Pharma","relationship":"Current Owner"},{"period":"2019","companyName":"Aspen Japan K.K.; Mitsubishi Tanabe Pharma Corporation","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"60%"},"publicationCount":18462,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L04AX01","allCodes":["L04AX01"]},"biosimilarFilings":[],"originalDeveloper":"Prometheus Labs","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Aaipharma Llc","Alkem Labs Ltd","Amneal","Rising","Zydus Pharms Usa"],"status":"approved","companyName":"Legacy Pharma","companyId":"legacy-pharma","modality":"Small molecule","firstApprovalDate":"1968","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-02-21T00:00:00.000Z","mah":"RISING","brand_name_local":null,"application_number":"ANDA075568"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-07-18T00:00:00.000Z","mah":"AAIPHARMA LLC","brand_name_local":null,"application_number":"ANDA075252"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-07-09T00:00:00.000Z","mah":"LEGACY PHARMA","brand_name_local":null,"application_number":"NDA016324"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-06-20T00:00:00.000Z","mah":"ZYDUS PHARMS USA","brand_name_local":null,"application_number":"ANDA077621"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-06-13T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA208687"},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":"EMEA/H/C/005055"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Jayempi","application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"1749.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"regulatorySummaries":{"US_FDA_approval_18460":{"country_code":"US","agency":"FDA","entity_type":"approval","entity_id":"18460","summary_short":"ALKEM LABS LTD received FDA marketing authorisation for Imuran on 2025-06-13 under application number ANDA208687.","summary_long":"ALKEM LABS LTD received marketing authorisation for Imuran from the FDA on 2025-06-13. The application number for this approval is ANDA208687. The approved indication for Imuran is labelled, but the specific details of the labelling are not provided.","key_points":["ALKEM LABS LTD received FDA marketing authorisation for Imuran on 2025-06-13.","The approved indication for Imuran is labelled, but specific details are not provided."],"citations":[{"source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA208687"}],"generated_at":"2026-05-18T08:06:12.717Z"}},"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:59:15.093526+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}